Article Abstract

When survival curves cross: are we at a crossroads of immunotherapy in gastric cancer?

Authors: Jun Gong, Joseph Chao

Abstract

The first U.S. Food and Drug Administration (FDA) approval of a programmed cell death protein (PD-1) inhibitor specifically for advanced gastroesophageal cancer occurred with the passing of pembrolizumab on September 22, 2017 (1).